Gilead Sciences, Inc.

NasdaqGS:GILD Stock Report

Market Cap: US$155.3b

Gilead Sciences Dividends and Buybacks

Dividend criteria checks 5/6

Gilead Sciences is a dividend paying company with a current yield of 2.51% that is well covered by earnings. Next payment date is on 30th December, 2025 with an ex-dividend date of 15th December, 2025.

Key information

2.5%

Dividend yield

1.0%

Buyback Yield

Total Shareholder Yield3.5%
Future Dividend Yield2.9%
Dividend Growth7.7%
Next dividend pay date30 Dec 25
Ex dividend date15 Dec 25
Dividend per sharen/a
Payout ratio48%

Recent dividend and buyback updates

Recent updates

Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

Nov 20

Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?

Jul 27
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?

Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are

May 15
Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are

Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance

Apr 25

Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price

Apr 15
Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price

New HIV, Livdelzi And CAR T Options Will Expand Reach

Gilead's innovation in HIV and oncology treatments supports revenue growth and market expansion in these therapeutic areas.

Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally

Mar 16

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Mar 12
Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Why Gilead Sciences Remains A Buy After A 40% Rally

Feb 27

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Feb 18
Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Gilead Sciences: Diversification Strategy Not Derisked Enough Yet

Feb 11

Gilead Sciences (NASDAQ:GILD) Could Easily Take On More Debt

Feb 09
Gilead Sciences (NASDAQ:GILD) Could Easily Take On More Debt

Gilead: Strong Sales Growth Remains With Veklury And Beyond

Feb 03

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise

Dec 29

Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure

Dec 18

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: GILD's dividends per share have been stable in the past 10 years.

Growing Dividend: GILD's dividend payments have increased over the past 10 years.

Dividend Yield vs Market

Gilead Sciences Dividend Yield vs Market
How does GILD dividend yield compare to the market?
SegmentDividend Yield
Company (GILD)2.5%
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.4%
Industry Average (Biotechs)2.4%
Analyst forecast (GILD) (up to 3 years)2.9%

Notable Dividend: GILD's dividend (2.51%) is higher than the bottom 25% of dividend payers in the US market (1.41%).

High Dividend: GILD's dividend (2.51%) is low compared to the top 25% of dividend payers in the US market (4.41%).

Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (48.2%), GILD's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (42.8%), GILD's dividend payments are well covered by cash flows.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/24 18:43
End of Day Share Price 2025/12/23 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gilead Sciences, Inc. is covered by 67 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Brian SkorneyBaird
James BirchenoughBarclays